{"id":969,"date":"2026-03-17T01:26:31","date_gmt":"2026-03-17T08:26:31","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=969"},"modified":"2026-03-17T01:26:33","modified_gmt":"2026-03-17T08:26:33","slug":"bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/","title":{"rendered":"BIMZELX vs\u00a0 SKYRIZI &#8211; one stands out in a head\u2011to\u2011head trial"},"content":{"rendered":"\n<p>A new head\u2011to\u2011head study found that bimekizumab (brand name <strong>BIMZELX<\/strong>) produced better short\u2011term joint improvement than risankizumab (brand name <strong>SKYRIZI<\/strong>) in adults with active psoriatic arthritis (PsA). The trial\u2019s primary measure was <strong>ACR50<\/strong>&nbsp; &#8211;&nbsp; a commonly used, fairly strict standard that means a patient has achieved at least a 50% improvement in joint signs and symptoms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What the BE BOLD study tested and why it matters<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Who was studied.<\/strong> BE BOLD enrolled adults with active psoriatic arthritis. The trial included people who were biologic\u2011na\u00efve or had limited prior biologic exposure, reflecting a broad group of patients seen in clinics.<\/li>\n\n\n\n<li><strong>What was compared.<\/strong> The study directly compared two approved biologic medicines: bimekizumab (which blocks both IL\u201117A and IL\u201117F) and risankizumab (which targets IL\u201123). These drugs work on different parts of the immune system that drive PsA.<\/li>\n\n\n\n<li><strong>Primary outcome.<\/strong> The main goal was the proportion of patients achieving <strong>ACR50<\/strong> at Week 16\u00a0 &#8211;\u00a0 a meaningful, joint\u2011focused measure that requires substantial improvement in tender and swollen joint counts plus other clinical measures. Meeting ACR50 is considered a robust sign that a treatment is controlling joint inflammation.<\/li>\n<\/ul>\n\n\n\n<p>Why this is important: direct comparisons between biologics using joint outcomes are rare in PsA. BE BOLD is the first head\u2011to\u2011head study to show superiority of a licensed biologic over an IL\u201123 inhibitor using a joint\u2011focused endpoint, which can help doctors and patients weigh options when choosing therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Summary of the results<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bimekizumab performed better on the main joint measure (ACR50) at Week 16.<\/strong> The company reported that a statistically greater share of people on bimekizumab reached ACR50 compared with those on risankizumab. That means more people had a large, clinically meaningful reduction in joint pain and swelling with bimekizumab in the early weeks of treatment.<\/li>\n\n\n\n<li><strong>Safety so far.<\/strong> In the topline announcement, bimekizumab was generally well tolerated and no new safety signals were seen through Week 16. Full safety details will be available when the complete dataset is presented.<\/li>\n<\/ul>\n\n\n\n<p>In this trial, more people taking BIMZELX had a strong improvement in their arthritis after about four months than people taking SKYRIZI, and no new short\u2011term safety concerns were reported in the topline release.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A quick comparison table<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Feature<\/strong><\/td><td><strong>BIMZELX (bimekizumab)<\/strong><\/td><td><strong>SKYRIZI (risankizumab)<\/strong><\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks IL\u201117A and IL\u201117F<\/td><td>Blocks IL\u201123<\/td><\/tr><tr><td><strong>Primary BE BOLD result<\/strong><\/td><td>Superior for ACR50 at Week 16 (statistically significant)<\/td><td>Comparator; did not meet superiority in ACR50<\/td><\/tr><tr><td><strong>Short\u2011term safety (to Week 16)<\/strong><\/td><td>Generally well tolerated; no new signals reported<\/td><td>Safety profile consistent with known label (trial report)<\/td><\/tr><tr><td><strong>Study type<\/strong><\/td><td>Phase 3, randomized, double\u2011blind, active\u2011controlled<\/td><td>Active comparator in same trial<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div class=\"wp-block-group is-style-default has-background has-global-padding is-layout-constrained wp-container-core-group-is-layout-384690f3 wp-block-group-is-layout-constrained\" style=\"background-color:#f0e9de;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--20);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--20)\">\n<figure class=\"wp-block-image aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"400\" src=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/directory-membership-benefits-1-e1770770324778.webp\" alt=\"\" class=\"wp-image-798\" style=\"object-fit:cover\"\/><\/figure>\n\n\n\n<div class=\"wp-block-buttons alignwide is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button pattern-info discover_button_pattern is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-base-color has-text-color has-link-color has-text-align-center wp-element-button\" href=\"https:\/\/www.getasecondopinion.ai\/signup\" style=\"border-style:none;border-width:0px;padding-top:var(--wp--preset--spacing--20);padding-right:55px;padding-bottom:var(--wp--preset--spacing--20);padding-left:55px;font-style:normal;font-weight:500\" target=\"_blank\" rel=\"noreferrer noopener\">See Your Ranked Personalized Treatments<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How the two drugs differ biologically<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL\u201123 inhibitors (like risankizumab)<\/strong> reduce activity of a pathway that helps certain immune cells produce inflammatory signals, including IL\u201117A and IL\u201117F. This can be very effective, especially for skin disease.<\/li>\n\n\n\n<li><strong>IL\u201117A\/IL\u201117F inhibitors (like bimekizumab)<\/strong> block the inflammatory molecules IL\u201117A and IL\u201117F directly. Because IL\u201117F can sometimes be produced independently of IL\u201123, blocking both IL\u201117A and IL\u201117F may give broader control of inflammation in some patients, particularly for joint symptoms. The BE BOLD study was designed to test whether that theoretical advantage translates into better joint outcomes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What to keep in mind when reading topline results<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Topline \u2260 full dataset.<\/strong> A press release gives the main outcome but not all the details. Full results\u00a0 &#8211;\u00a0 including exact response rates, confidence intervals, subgroup analyses, and complete safety data\u00a0 &#8211;\u00a0 are usually presented at medical meetings or published in journals later.<\/li>\n\n\n\n<li><strong>Short\u2011term vs long\u2011term.<\/strong> The primary result reported was at Week 16. Long\u2011term effectiveness and safety (months to years) are important for chronic conditions like PsA and will need full reporting and follow\u2011up.<\/li>\n\n\n\n<li><strong>Individual response varies.<\/strong> Even if a drug shows superiority on average, some patients respond better to one medicine than another. Treatment choice should consider a person\u2019s overall disease pattern (joints, skin, nails), other health conditions, prior treatments, and personal preferences.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What this might mean for people living with PsA<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>More evidence to guide choices.<\/strong> Head\u2011to\u2011head trials help clinicians and patients compare options directly rather than relying on separate trials that enrolled different populations. BE BOLD adds a meaningful piece of evidence about joint outcomes.<\/li>\n\n\n\n<li><strong>Not a one\u2011size\u2011fits\u2011all answer.<\/strong> Some people may prioritize skin clearance, others joint control, and some may weigh safety or dosing convenience more heavily. A doctor will consider the full clinical picture.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What to watch next<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full data release.<\/strong> UCB has said it will submit the full BE BOLD results to an international congress and publish the complete dataset. That will include exact numbers, subgroup analyses, and more detailed safety information.<\/li>\n\n\n\n<li><strong>Independent analyses and peer review.<\/strong> Once the full data are available in a peer\u2011reviewed journal or conference presentation, independent experts will evaluate the findings and place them in context with other studies.<\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Sources (3)<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li>UCB press release: BIMZELX (bimekizumab) superior to SKYRIZI (risankizumab) in BE BOLD.<br><a href=\"https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/bimzelxrvbimekizumab-superior-to-skyrizir-risankizumab-in-be-bold-first-head-to-head-study-in-active-psoriatic-arthritis-psa-to-demonstrate-superiority-in-acr50\">https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/bimzelxrvbimekizumab-superior-to-skyrizir-risankizumab-in-be-bold-first-head-to-head-study-in-active-psoriatic-arthritis-psa-to-demonstrate-superiority-in-acr50<\/a>\u00a0<\/li>\n\n\n\n<li>ClinicalTrials.gov record for BE BOLD\u00a0 &#8211;\u00a0 <strong>NCT06624228<\/strong> (study design, enrollment, and status).<br><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06624228\">https:\/\/clinicaltrials.gov\/study\/NCT06624228<\/a>\u00a0\u00a0<\/li>\n\n\n\n<li>Study design and rationale summary for BE BOLD (head\u2011to\u2011head rationale comparing IL\u201117A\/IL\u201117F vs IL\u201123 approaches).<br>Journal abstract and conference materials; see the Journal of the American Academy of Dermatology \/ related conference abstracts.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>A new head\u2011to\u2011head study found that bimekizumab (brand name BIMZELX) produced better short\u2011term joint improvement than risankizumab (brand name SKYRIZI) in adults with active psoriatic arthritis (PsA). The trial\u2019s primary measure was ACR50&nbsp; &#8211;&nbsp; a commonly used, fairly strict standard that means a patient has achieved at least a 50% improvement in joint signs and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":970,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[714,715,709,708,711,710,717,716,712,713],"class_list":["post-969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medications","tag-acr50-results","tag-arthritis-treatment","tag-be-bold-study","tag-bimekizumab","tag-bimzelx","tag-biologic-comparison","tag-joint-inflammation","tag-psoriatic-arthritis","tag-risankizumab","tag-skyrizi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T08:26:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T08:26:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"BIMZELX vs\u00a0 SKYRIZI &#8211; one stands out in a head\u2011to\u2011head trial\",\"datePublished\":\"2026-03-17T08:26:31+00:00\",\"dateModified\":\"2026-03-17T08:26:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\"},\"wordCount\":907,\"publisher\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg\",\"keywords\":[\"ACR50 results\",\"arthritis treatment\",\"BE BOLD study\",\"bimekizumab\",\"BIMZELX\",\"biologic comparison\",\"joint inflammation\",\"psoriatic arthritis\",\"risankizumab\",\"SKYRIZI\"],\"articleSection\":[\"Medications\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\",\"url\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\",\"name\":\"BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg\",\"datePublished\":\"2026-03-17T08:26:31+00:00\",\"dateModified\":\"2026-03-17T08:26:33+00:00\",\"description\":\"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage\",\"url\":\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg\",\"contentUrl\":\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Digital medical illustration showing inflamed joints in a human hand and figure, with BIMZELX and SKYRIZI vials side-by-side and article title text clearly displayed in white against a blue gradient background.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\/\/www.getasecondopinion.ai\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medications\",\"item\":\"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BIMZELX vs\u00a0 SKYRIZI &#8211; one stands out in a head\u2011to\u2011head trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#website\",\"url\":\"https:\/\/www.getasecondopinion.ai\/blog\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\/\/www.getasecondopinion.ai\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png\",\"contentUrl\":\"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/getasecondopinion\",\"https:\/\/www.instagram.com\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion","description":"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/","og_locale":"en_US","og_type":"article","og_title":"BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion","og_description":"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2026-03-17T08:26:31+00:00","article_modified_time":"2026-03-17T08:26:33+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"BIMZELX vs\u00a0 SKYRIZI &#8211; one stands out in a head\u2011to\u2011head trial","datePublished":"2026-03-17T08:26:31+00:00","dateModified":"2026-03-17T08:26:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/"},"wordCount":907,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg","keywords":["ACR50 results","arthritis treatment","BE BOLD study","bimekizumab","BIMZELX","biologic comparison","joint inflammation","psoriatic arthritis","risankizumab","SKYRIZI"],"articleSection":["Medications"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/","name":"BIMZELX vs\u00a0 SKYRIZI - one stands out in a head\u2011to\u2011head trial - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg","datePublished":"2026-03-17T08:26:31+00:00","dateModified":"2026-03-17T08:26:33+00:00","description":"BIMZELX outperforms SKYRIZI in joint improvement for psoriatic arthritis, BE BOLD study shows.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/03\/Bimzelx-vs-Skyrizi.jpg","width":1536,"height":1024,"caption":"Digital medical illustration showing inflamed joints in a human hand and figure, with BIMZELX and SKYRIZI vials side-by-side and article title text clearly displayed in white against a blue gradient background."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/bimzelx-vs-skyrizi-one-stands-out-in-a-head-to-head-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Medications","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/"},{"@type":"ListItem","position":3,"name":"BIMZELX vs\u00a0 SKYRIZI &#8211; one stands out in a head\u2011to\u2011head trial"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=969"}],"version-history":[{"count":1,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/969\/revisions"}],"predecessor-version":[{"id":971,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/969\/revisions\/971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/970"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}